NO20076398L - Preventivt eller terapeutisk middel for keratokonjunktive forstyrrelser - Google Patents

Preventivt eller terapeutisk middel for keratokonjunktive forstyrrelser

Info

Publication number
NO20076398L
NO20076398L NO20076398A NO20076398A NO20076398L NO 20076398 L NO20076398 L NO 20076398L NO 20076398 A NO20076398 A NO 20076398A NO 20076398 A NO20076398 A NO 20076398A NO 20076398 L NO20076398 L NO 20076398L
Authority
NO
Norway
Prior art keywords
preventive
corneal
therapeutic agent
keratoconjunctivitis
phenyl
Prior art date
Application number
NO20076398A
Other languages
English (en)
Inventor
Masatsugu Nakamura
Atsushi Yoshida
Shinichirou Hirai
Original Assignee
Santen Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Santen Pharmaceutical Co Ltd filed Critical Santen Pharmaceutical Co Ltd
Publication of NO20076398L publication Critical patent/NO20076398L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/26—Cyanate or isocyanate esters; Thiocyanate or isothiocyanate esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Det tilveiebringes en ny medisinsk anvendelse av 2-fenyl-1,2-benzisoselenazol-3-(2H)-on eller et salt derav. 2-fenyl-1,2-benzisoselenazol-3-(2H)-on eller et salt derav viser en utmerket preventiv og forbedrende effekt i korneale forstyrrelsesmodeller og er derfor nyttig som et preventivt eller terapeutisk middel mot en keratokonjunktival forstyrrelse som tørt øye, overflatisk punktat keratopati, korneal epiteliale defekter, korneal erosjon, korneal ulcer, konjunktival epiteliale defekter, keratokonjunktivitis sicca, superior limbisk keratokonjunktivitis, filamentær keratokonjunktivitis, keratitt eller konjunktivitt.
NO20076398A 2005-05-17 2007-12-11 Preventivt eller terapeutisk middel for keratokonjunktive forstyrrelser NO20076398L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2005143477 2005-05-17
PCT/JP2006/309797 WO2006123676A1 (ja) 2005-05-17 2006-05-17 角結膜障害の予防または治療剤

Publications (1)

Publication Number Publication Date
NO20076398L true NO20076398L (no) 2008-02-11

Family

ID=37431248

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20076398A NO20076398L (no) 2005-05-17 2007-12-11 Preventivt eller terapeutisk middel for keratokonjunktive forstyrrelser

Country Status (14)

Country Link
US (2) US8222283B2 (no)
EP (1) EP1884234B1 (no)
KR (1) KR101286883B1 (no)
CN (1) CN101175487B (no)
CA (1) CA2608457C (no)
CY (1) CY1113161T1 (no)
DK (1) DK1884234T3 (no)
ES (1) ES2389566T3 (no)
NO (1) NO20076398L (no)
PL (1) PL1884234T3 (no)
PT (1) PT1884234E (no)
RU (1) RU2406499C2 (no)
SI (1) SI1884234T1 (no)
WO (1) WO2006123676A1 (no)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8222283B2 (en) 2005-05-17 2012-07-17 Santen Pharmaceutical Co., Ltd. Method for treating a keratoconjunctival disorder
KR20100016140A (ko) 2007-05-25 2010-02-12 산텐 세이야꾸 가부시키가이샤 가령 황반 변성의 예방 또는 치료제
CA2716466A1 (en) * 2008-02-28 2009-09-03 Santen Pharmaceutical Co., Ltd. Prophylactic or therapeutic agent for eye disease accompanied by optic nerve disorder
RU2459615C1 (ru) * 2011-03-05 2012-08-27 Илья Александрович Марков Глазные капли для лечения болезни сухого глаза
CN107550920A (zh) * 2011-11-24 2018-01-09 东洋精糖株式会社 角结膜保护剂或角结膜障碍抑制剂
RU2522381C1 (ru) * 2013-01-24 2014-07-10 федеральное государственное бюджетное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова" Министерства здравоохранения Российской Федерации Способ лечения трофических эрозий роговицы
KR101692578B1 (ko) * 2013-04-18 2017-01-03 삼진제약주식회사 레바미피드 또는 이의 전구체를 포함하는 안구건조증의 예방 또는 치료를 위한 경구용 약제학적 조성물
RU2544225C1 (ru) * 2013-12-13 2015-03-10 федеральное государственное бюджетное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова" Министерства здравоохранения Российской Федерации Способ лечения послеоперационных эрозий роговицы после удаления птеригиума
US10058542B1 (en) 2014-09-12 2018-08-28 Thioredoxin Systems Ab Composition comprising selenazol or thiazolone derivatives and silver and method of treatment therewith
WO2017070637A1 (en) 2015-10-23 2017-04-27 The Trustees Of Columbia University In The City Of New York Laser induced collagen crosslinking in tissue
GB2550110A (en) 2016-04-28 2017-11-15 Univ Oxford Innovation Ltd Treatment of impulsivity-related disorders
US11497403B2 (en) 2016-06-10 2022-11-15 The Trustees Of Columbia University In The City Of New York Devices, methods, and systems for detection of collagen tissue features
EP3668836A4 (en) * 2017-08-18 2021-04-07 The Schepens Eye Research Institute, Inc. DRY EYE TREATMENT COMPOSITIONS AND METHODS OF APPLYING THEREOF
GB201717629D0 (en) 2017-10-26 2017-12-13 Univ Oxford Innovation Ltd Treatment of unipolar depressive disorder
US11666481B1 (en) 2017-12-01 2023-06-06 The Trustees Of Columbia University In The City Of New York Diagnosis and treatment of collagen-containing tissues
EP4536191A1 (en) * 2022-06-06 2025-04-16 Sound Pharmaceuticals Incorporated Ebselen containing oral dosage forms

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3616923A1 (de) * 1986-05-20 1987-11-26 Nattermann A & Cie Neue pharmazeutische verwendung von 2-phenyl-1,2-benzisoselenazol-3(2h)-on
US4778814A (en) * 1987-03-18 1988-10-18 Ciba-Geigy Corporation Method of treating ocular allergy by topical application of a 2-substituted-1,2-benzisoselenazol-3(2H)-one
ES2145065T3 (es) * 1993-10-27 2000-07-01 Daiichi Seiyaku Co Preparacion granular.
CA2224563A1 (en) * 1995-06-12 1996-12-27 G.D. Searle & Co. Combination of a cyclooxygenase-2 inhibitor and a leukotriene b4 receptor antagonist for the treatment of inflammations
FR2740339B1 (fr) * 1995-10-26 1997-12-05 Oreal Utilisation d'au moins un inhibiteur de no-synthase dans le traitement des peaux sensibles
FR2757860B1 (fr) * 1996-12-27 1999-04-23 Oxis International Sa Composes organoselenies cycliques, leur preparation et leurs utilisations, notamment therapeutiques
JP2001261555A (ja) 2000-03-17 2001-09-26 Dai Ichi Seiyaku Co Ltd 脳動脈中膜肥厚抑制剤
FR2815541B1 (fr) * 2000-10-24 2008-02-29 Lipha Utilisation d'inhibiteurs de l'apoptose des pericytes pour le traitement et/ou la prevention de la retinopathie diabetique
US7732487B2 (en) * 2001-11-19 2010-06-08 Sucampo Ag Method for treating a disease or condition responsive to opening of C1C-2 channel
WO2004069157A2 (en) 2003-01-17 2004-08-19 Ophthalmic Research Associates, Inc. Combinational use of long-acting and short-acting anti-histamines for ocular allergies
CA2488143A1 (en) 2003-02-07 2004-08-26 The General Hospital Corporation Methods and compositions for modulating glutamate transport activity in the nervous system
JP2006104199A (ja) 2004-09-13 2006-04-20 Santen Pharmaceut Co Ltd 角結膜障害治療剤
US8222283B2 (en) 2005-05-17 2012-07-17 Santen Pharmaceutical Co., Ltd. Method for treating a keratoconjunctival disorder
JP2008013448A (ja) 2006-07-03 2008-01-24 Gifu Prefecture 視神経細胞保護剤
KR20100016140A (ko) 2007-05-25 2010-02-12 산텐 세이야꾸 가부시키가이샤 가령 황반 변성의 예방 또는 치료제
CA2716466A1 (en) * 2008-02-28 2009-09-03 Santen Pharmaceutical Co., Ltd. Prophylactic or therapeutic agent for eye disease accompanied by optic nerve disorder

Also Published As

Publication number Publication date
EP1884234A4 (en) 2010-01-13
US8222283B2 (en) 2012-07-17
US8536207B2 (en) 2013-09-17
RU2007146688A (ru) 2009-06-27
KR101286883B1 (ko) 2013-07-16
CA2608457A1 (en) 2006-11-23
US20090105313A1 (en) 2009-04-23
PL1884234T3 (pl) 2012-11-30
EP1884234A1 (en) 2008-02-06
KR20080016556A (ko) 2008-02-21
RU2406499C2 (ru) 2010-12-20
CN101175487A (zh) 2008-05-07
EP1884234B1 (en) 2012-07-18
SI1884234T1 (sl) 2012-10-30
US20120232119A1 (en) 2012-09-13
CN101175487B (zh) 2011-11-16
DK1884234T3 (da) 2012-10-08
WO2006123676A1 (ja) 2006-11-23
CY1113161T1 (el) 2016-04-13
ES2389566T3 (es) 2012-10-29
CA2608457C (en) 2013-09-10
PT1884234E (pt) 2012-07-26

Similar Documents

Publication Publication Date Title
CY1113161T1 (el) Προφυλακτικος ή θεραπευτικος παραγων για κερατοειδικη και επιπεφυκιτιδιακη διαταραχη
AU2012356133B2 (en) A rapid quantitative assay to measure CFTR function in a primary intestinal culture model
DK1679074T3 (da) Terapeutisk middel til keratoconjunktive forstyrrelser
NO20082481L (no) Nye 2-aminoheterosykluser som er nyttige ved behandling av ABETA-relaterte patologier
NO20082090L (no) Pyridopyrimidinoninhibitorer av P13K alfa
PE20081404A1 (es) Derivados de sulfonil-fenil-2h-[1,2,4]oxadiazol-5-ona y procesos para su preparacion
EA201792602A1 (ru) Стволовые клетки плацентарного происхождения и их применение для восстановления регенеративного механизма, коррекции протеомных дефектов и продления жизни стареющих индивидуумов
NO20061454L (no) Compounds having CRTH2 antagonist activity
NO20075560L (no) Purin og imidazopyridin derivater for immunsuppresjon
MA31090B1 (fr) Derives de dihydropyridine utiles en tant qu'inhibiteurs de la proteine kinase
PE20110598A1 (es) Inhibidores de las enzimas de proteina cinasa activadas por mitogeno p38
NO20071197L (no) Sulfonamidderivater, deres fremstilling og deres terapeutiske anvendelse
PE20091484A1 (es) PIRIDINONAS Y PIRIDAZINONAS QUE INHIBEN LA Btk
EA200870396A1 (ru) Лечение аллергических заболеваний глаз
EA200901514A1 (ru) Новая сольватная и кристаллическая форма производных карбамоилциклогексана
AR065509A1 (es) Derivados heterociclicos de imidazol, composiciones farmaceuticas que los comprenden y uso de los mismos en trastornos inflamatorios y autoinmunes.
CY1113651T1 (el) Αντιφλεγμονωδη σκευασματα
NO20081945L (no) Forbindelser som har aktivitet som M1 receptor og deres medisinske anvendelse
NO20072005L (no) Nye heterocykliske amider
DE602005010970D1 (de) Indol-derivate und ihre verwendung als kinase-hemmer, insbesondere ikk2-hemmer
ATE535603T1 (de) Mutante reverse transkriptase und verwendungsverfahren
AR054688A1 (es) Alquil-piridinas como inhibidores 11-beta de la diabetes
EA201070366A1 (ru) 3-метил-2-((2s)-2-(4-(3-метил-1,2,4-оксадиазол-5-ил)фенил)морфолино)-6-(пиримидин-4-ил)пиримидин-4(3н)-он в качестве ингибитора тау-протеинкиназы
Shastry et al. Homocysteine induces mesangial cell apoptosis via activation of p38-mitogen-activated protein kinase
NO20081014L (no) Sammensetninger

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application